Lepu Biopharma

Executive Summary

Lepu Biopharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of innovative oncology and immunology therapeutics. Leveraging its proprietary antibody engineering platform, the company designs novel bispecific antibodies and antibody-drug conjugates (ADCs) aimed at addressing significant unmet medical needs in cancer and autoimmune diseases. Founded in 2018, Lepu has advanced several candidates into Phase 2 trials, positioning itself as a promising player in China's competitive biotech landscape. Despite being early-stage, the company's focus on differentiated biologics and its public listing provide a foundation for potential value creation through clinical milestones and strategic collaborations. Key strengths include a robust pipeline of next-generation immunotherapies and a management team with deep expertise in antibody engineering. Near-term catalysts include data readouts from ongoing Phase 2 studies, regulatory progress for new drug applications, and potential partnership deals to expand its reach. However, as a clinical-stage company, Lepu faces typical risks such as clinical trial failures, regulatory hurdles, and financing needs. The success of its lead ADC and bispecific candidates will be critical to validating its platform and driving shareholder value.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead ADC candidate in solid tumors40% success
• Q3 2026IND approval for novel bispecific antibody targeting autoimmune indications60% success
• H2 2026Strategic partnership or licensing deal for pipeline assets30% success